SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as discussions swirl around its AI capabilities, particularly the Gemini 3 model, and its potential impact on competitors like NVDA. The community is weighing whether GOOG is becoming the dominant AI player, with some citing its custom silicon and potential for monetization. There's also buzz about the stock's valuation and recent analyst commentary.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors weigh its AI prospects following positive reviews of its Gemini 3 model and news of Berkshire Hathaway taking a stake. Community discussions highlight GOOGL's potential to challenge competitors like NVDA and OpenAI, with some seeing it as undervalued. Bullish sentiment centers around Google's diverse AI capabilities and potential for future growth in the tech sector.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending due to its impending addition to the S&P 500, driving significant after-hours movement and sparking debate about whether the inclusion was leaked beforehand. The community is actively discussing the potential for further gains, contrasting opinions on shorting the stock, and the impact of memory storage demand in the AI sector. Others are pondering if the stock is overvalued after its recent runup.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target ($TGT) is trending as investors weigh its upcoming earnings report amid concerns about consumer spending and competition from other retailers. The community is split, with some anticipating a potential value play due to its discounted valuation and dividend yield, while others fear further downside based on recent performance and economic headwinds. Discussions also include Target's AI initiatives and potential as a buyout target.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic is trending following its Q3 earnings release, sparking mixed reactions in the community. While the company exceeded revenue expectations, some investors are wary of the outlook and valuation, given its reliance on Walmart, triggering profit-taking. However, long-term bulls remain confident in SYM's growth potential within the warehouse automation and robotics space.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

SGML is trending due to renewed interest in lithium stocks, fueled by supply concerns stemming from potential mining license issues in China and positive price forecasts. Community discussions revolve around whether recent gains are sustainable, with some citing short squeeze potential while others point to insider selling and caution against overvaluation. The broader lithium sector and SGML's production capacity are key factors in the ongoing debate.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to a reported Q3 revenue jump and shift towards AI/GPU compute hosting, sparking community interest in its potential as a digital infrastructure play. Discussions revolve around its low float, recent reverse split, and possible short squeeze, with some seeing significant upside based on assets and sector comparisons. Some investors believe that the company is undervalued, especially in light of the rise of Bitcoin and AI.

shark raptor rocket launcher

SRRL (shark raptor rocket launcher) is trending as social media buzz points to a potential surge, with community members expressing strong confidence. Conversations suggest growing interest and speculation about a possible pump, while some caution about ownership concentration.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad ($MON) is gaining attention as traders discuss its potential, comparing it to established players like Solana ($SOL) and Bitcoin ($BTC). Community members are actively debating potential price movements and whether the current activity is a pump or the formation of a stable base. Concerns about VC involvement and potential rugs are also circulating within the community.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is trending due to positive sentiment following their Q4 earnings report and subsequent FY26 guidance, with community members highlighting the increased backlog and revenue expectations. Discussions revolve around the company's position in the growing BESS (Battery Energy Storage System) market and potential for significant growth, especially with AI driving demand for more power. Some are speculating on a potential short squeeze and potential takeover by BlackRock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Pasithea Therapeutics garnered heightened retail buzz on Tuesday after the firm announced preclinical results showing that its experimental drug, PAS-004, effectively blocked ETS2 signaling, which controls inflammation in IBD and other immune conditions.Research from the Francis Crick Institute found PAS-004 more effective than selumetinib at reducing the expression of ETS2-regulated genes and macrophage functions essential for cytokine production and phagocytosis.Pasithea Therapeutics shares ended Tuesday at $0.98, with a 3.77% gain, but they fell back 4.17% to $0.94 during after-hours trading.According to Lee, who published a 2024 Nature paper identifying ETS2 as an essential regulator of IBD-related inflammation, the findings suggest PAS-004 could provide broader inhibition of inflammatory pathways compared to selumetinib and therapies that target individual cytokines or rely on JAK inhibition.According to Pasithea CEO Tiago Reis Marques, data findings show PAS-004's potential for treating chronic inflammatory diseases and its existing cancer application.&nbsp;Safety data from Phase 1 trials in advanced cancer patients suggest that the drug appears to show good tolerance in wider therapeutic uses.The firm announced its plan to move PAS-004 into proof-of-concept research targeting inflammatory disorders, including IBD and ankylosing spondylitis.On Stocktwits, retail sentiment was ‘bullish’ amid a 7,450% surge in 24-hour message volume.One user&nbsp;was “infuriated” after exiting a position in Pasithea Therapeutics (KTTA) at a loss after buying in at $1.18 and selling at $0.92, only to see the stock rise afterward.<stembedurl>https://stocktwits.com/Cdeezhands/message/615259857</stembedurl>Another user noted that Pasithea’s recent news was encouraging and pointed to the stock’s price movement from around $2.08 in April to $2.48 in early May as a sign of potential for organic upside.<stembedurl>https://stocktwits.com/stocktrade77/message/615239372</stembedurl>The stock has declined 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Pasithea Therapeutics Stock Draws Retail Buzz As Early Data Shows Potential In Treating Inflammatory Diseases

The company saw increased retail chatter after new preclinical data showed its drug, PAS-004, effectively blocks inflammation pathways linked to IBD and other immune diseases. 

Equity

The company saw increased retail chatter after new preclinical data showed its drug, PAS-004, effectively blocks inflammation pathways linked to IBD and other immune diseases. The company plans to advance PAS-004 into further studies targeting inflammatory conditions.

Shares of Theriva Biologics fell sharply after the company priced a public offering of up to 6.8 million shares of common stock and accompanying warrants at $1.10 per unit.&nbsp;The offering is expected to raise nearly $7.5 million in gross proceeds, before deducting placement agent fees and other offering expenses.&nbsp;The warrants will be exercisable immediately at the same price of $1.10 per share and will expire in five years.Theriva shares closed at $0.81, down 41% on Wednesday. After hours, shares dropped to $0.75, reflecting a further 7.4% decline.The offering follows the announcement of positive topline results from the Virage Phase 2b clinical trial, which evaluated VCN-01 in combination with standard chemotherapy for treating metastatic pancreatic ductal adenocarcinoma (PDAC).&nbsp;The study, which included 96 newly diagnosed metastatic PDAC patients, showed that patients receiving VCN-01 plus chemotherapy had a median overall survival (OS) of 10.8 months, compared to 8.6 months in the control group receiving chemotherapy alone.&nbsp;Additionally, the VCN-01+chemotherapy arm showed a median duration of response (DoR) of 11.2 months, double that of the control arm’s 5.4 months.Theriva intends to use the proceeds primarily for working capital, general corporate purposes, and research and development.&nbsp;A portion of the funds may also be used for manufacturing scale-up or potential acquisitions, although no specific deals are currently in place.&nbsp;A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.On Stocktwits, sentiment was described as ‘extremely bullish’, with ‘high’ message volume fueling speculation about the company’s future.&nbsp;One user speculated that a buyout could still be in play, potentially happening before September 30. This user noted that while the offering would dilute the stock, buying at current levels could offer significant upside in the event of a buyout.<stembedurl>https://stocktwits.com/exwallstcfo/message/613861348</stembedurl>Another user drew comparisons between Theriva and Pasithea Therapeutics, suggesting that both companies had positive news followed by public offerings.&nbsp;The user speculated that the offering could have been strategically timed to benefit from a price pump.<stembedurl>https://stocktwits.com/Staceykyusa/message/613855430</stembedurl>Shares of Theriva have fallen nearly 51% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a chart depicting stock market crash, is displayed on a mobile phone screen in Ankara, Turkiye on August 5, 2024. (Photo by Osmancan Gurdogan/Anadolu via Getty Images)

Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01.

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01, in combination with standard chemotherapy. 

Shares of Pasithea Therapeutics Corp. (KTTA) soared as high as about 150% on Tuesday morning before paring back most of the gains after it announced positive data from its ongoing Phase 1 trial of PAS-004 in advanced cancer patients.PAS-004 is a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) and other mitogen-activated protein kinase (MAPK) pathway driven cancer indications.The clinical-stage biotechnology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/06/3074902/0/en/Pasithea-Therapeutics-Reports-Positive-Pharmacodynamic-Results-Demonstrating-Robust-Target-Engagement-from-its-Ongoing-Phase-1-Clinical-Trial-of-PAS-004.html">said</a> that several patients achieved stable disease and tumor shrinkage while on the treatment.A patient being treated with 15-milligram capsules of PAS-004 with stage 4 pancreatic cancer achieved a tumor volume reduction of 9.8% over 5 months of PAS-004 treatment, the company said. The patients currently remain in the study, it added.Certain biomarkers also confirmed the capsule’s MEK inhibitor activity and substantial target engagement, the company said.The Phase 1 trial is aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004 in patients with MAPK pathway-driven advanced solid tumors.The recently announced data include results from patients treated with 8mg, 15mg, and 4mg tablets of PAS-004.In April, the company also dosed three subjects with 30mg capsules of PAS-004.The company then said it expects to complete enrollment of all patients in the trial by the end of 2025.On Stocktwits, retail sentiment around Pasithea jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:633/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_06_at_10_44_26_AM_png_4ec77b8998.webp" alt="KTTA's Sentiment Meter and Message Volume as of 10:45 a.m. ET on May 6, 2025 | Source: Stocktwits" width="633" height="62"><figcaption>KTTA's Sentiment Meter and Message Volume as of 10:45 a.m. ET on May 6, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/KTTA">KTTA stock</a> is down by about 42% this year and by about 76% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/economist-kenneth-rogoff-believes-trump-trade-policy-is-speeding-up-dollar-decline/chiIJtJRbS7">Economist Kenneth Rogoff Believes Trump’s Trade Policy Is Speeding Up Dollar’s Decline, Calls Navarro President’s ‘Rasputin’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated

The clinical-stage biotechnology company said several patients achieved stable disease and tumor shrinkage while on the treatment.

Shares of Pasithea Therapeutics Corp. (KTTA) surged nearly 47% on Thursday, closing at a two-month high, after an external committee approved advancing its cancer drug trial to the next dosing cohort.The news also resulted in the company's stock drawing the highest jump in retail investor chatter among healthcare stocks on Stocktwits.&nbsp;Message volume about KTTA soared by a whopping 48,000% by late Thursday, while sentiment flipped to 'extremely bullish' from 'bearish' a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/KTTA_sentiment_and_message_volume_April_10_png_57f0ce9213.webp" alt="KTTA sentiment and message volume April 10.png" width="1318" height="316"><figcaption>KTTA sentiment and message volume April 10. | source: Stocktwits</figcaption></figure>Pasithea said that its Phase 1 clinical trial of PAS-004 for advanced cancer has been cleared to advance to Cohort 6 (30mg capsule), following a recommendation from the independent Safety Review Committee.&nbsp;The decision was based on safety data from three patients in Cohort 5, with no dose-limiting toxicities (DLTs) reported.Notably, none of the first 19 patients — across both capsule and tablet formulations — have experienced rash, a common and often dose-limiting side effect seen with competitor MEK inhibitors.The ongoing trial is a multi-center, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004.&nbsp;One bullish watcher said the stock "will probably open at $2.18" on Friday, implying a more than 35% jump from the last close.<stembedurl>https://stocktwits.com/Nifty_Trader/message/611306648</stembedurl>Another user recommended holding the stock for a week or two and it "should be at $5 or $7."<stembedurl>https://stocktwits.com/MommoTrader/message/611306390</stembedurl><a href="https://stocktwits.com/symbol/KTTA">Pasithea stock</a> has lost nearly 50% this year. Shares were up marginally in Thursday's after-hours trading.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort

The decision was based on safety data from three patients in Cohort 5, with no dose-limiting toxicities reported.

11 Undervalued Stocks for Less Than $50 in April 2024

These inexpensive and undervalued stocks are top performers with strong upside potential based on their price-to-book ratio

 Steve Russell / Contributor

Neuroscience-focused biotechnology firm...

Pasithea Therapeutics Corp trading halted, volatility trading pause

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern...

Pasithea Therapeutics announces invention of crystalline form of PAS-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

-- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio -- SOUTH SAN FRANCISCO...

Pasithea Therapeutics announces FDA acceptance of IND application for PAS-004

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Lawrence J. Steinman on May 12, 2020 and is headquartered in Miami Beach, FL.

Pasithea Therapeutics Corp

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

Current Price	$0.4248
Prev Close	$0.2923
Open	$0.4201
Dividend Yield	0.00%
50-Day Moving Average	$0.7158
Beta	-0.08
Avg. Volume	98,340.17
PE Ratio	-0.08

52-Week High	$3.85
52-Week Low	$0.281
Market Capitalization	$2.18M
EPS (Annual)	-$12.69
Price to Book	0.26
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

KTTA
Pasithea Therapeutics Corp

Feed

News

Sentiment

Fundamentals

Info

Latest KTTA News

KTTAPasithea Therapeutics Corp